Literature DB >> 23728362

Broad protection against influenza infection by vectored immunoprophylaxis in mice.

Alejandro B Balazs1, Jesse D Bloom, Christin M Hong, Dinesh S Rao, David Baltimore.   

Abstract

Neutralizing antibodies that target epitopes conserved among many strains of influenza virus have been recently isolated from humans. Here we demonstrate that adeno-associated viruses (AAV) encoding two such broadly neutralizing antibodies are protective against diverse influenza strains. Serum from mice that received a single intramuscular AAV injection efficiently neutralized all H1, H2 and H5 influenza strains tested. After infection with diverse strains of H1N1 influenza, treated mice showed minimal weight loss and lung inflammation. Protection lasted for at least 11 months after AAV injection. Notably, even immunodeficient and older mice were protected by this method, suggesting that expression of a monoclonal antibody alone is sufficient to protect mice from illness. If translated to humans, this prophylactic approach may be uniquely capable of protecting immunocompromised or elderly patient populations not reliably protected by existing vaccines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23728362      PMCID: PMC4030719          DOI: 10.1038/nbt.2618

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  30 in total

1.  Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic.

Authors:  Niall P A S Johnson; Juergen Mueller
Journal:  Bull Hist Med       Date:  2002       Impact factor: 1.314

Review 2.  Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis.

Authors:  Harish Nair; W Abdullah Brooks; Mark Katz; Anna Roca; James A Berkley; Shabir A Madhi; James Mark Simmerman; Aubree Gordon; Masatoki Sato; Stephen Howie; Anand Krishnan; Maurice Ope; Kim A Lindblade; Phyllis Carosone-Link; Marilla Lucero; Walter Ochieng; Laurie Kamimoto; Erica Dueger; Niranjan Bhat; Sirenda Vong; Evropi Theodoratou; Malinee Chittaganpitch; Osaretin Chimah; Angel Balmaseda; Philippe Buchy; Eva Harris; Valerie Evans; Masahiko Katayose; Bharti Gaur; Cristina O'Callaghan-Gordo; Doli Goswami; Wences Arvelo; Marietjie Venter; Thomas Briese; Rafal Tokarz; Marc-Alain Widdowson; Anthony W Mounts; Robert F Breiman; Daniel R Feikin; Keith P Klugman; Sonja J Olsen; Bradford D Gessner; Peter F Wright; Igor Rudan; Shobha Broor; Eric A F Simões; Harry Campbell
Journal:  Lancet       Date:  2011-11-10       Impact factor: 79.321

3.  Infectious diseases. Controversial studies give a deadly flu virus wings.

Authors:  Martin Enserink
Journal:  Science       Date:  2011-12-02       Impact factor: 47.728

4.  Highly conserved protective epitopes on influenza B viruses.

Authors:  Cyrille Dreyfus; Nick S Laursen; Ted Kwaks; David Zuijdgeest; Reza Khayat; Damian C Ekiert; Jeong Hyun Lee; Zoltan Metlagel; Miriam V Bujny; Mandy Jongeneelen; Remko van der Vlugt; Mohammed Lamrani; Hans J W M Korse; Eric Geelen; Özcan Sahin; Martijn Sieuwerts; Just P J Brakenhoff; Ronald Vogels; Olive T W Li; Leo L M Poon; Malik Peiris; Wouter Koudstaal; Andrew B Ward; Ian A Wilson; Jaap Goudsmit; Robert H E Friesen
Journal:  Science       Date:  2012-08-09       Impact factor: 47.728

5.  Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.

Authors:  Jesse D Bloom; Lizhi Ian Gong; David Baltimore
Journal:  Science       Date:  2010-06-04       Impact factor: 47.728

6.  Development of formulations that enhance physical stability of viral vectors for gene therapy.

Authors:  M A Croyle; X Cheng; J M Wilson
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

7.  A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin.

Authors:  Jens C Krause; Tshidi Tsibane; Terrence M Tumpey; Chelsey J Huffman; Christopher F Basler; James E Crowe
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

8.  Estimates of deaths associated with seasonal influenza --- United States, 1976-2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-08-27       Impact factor: 17.586

9.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  68 in total

1.  A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status.

Authors:  Floriane Fusil; Sara Calattini; Fouzia Amirache; Jimmy Mancip; Caroline Costa; Justin B Robbins; Florian Douam; Dimitri Lavillette; Mansun Law; Thierry Defrance; Els Verhoeyen; François-Loïc Cosset
Journal:  Mol Ther       Date:  2015-08-18       Impact factor: 11.454

Review 2.  The potential of adeno-associated viral vectors for gene delivery to muscle tissue.

Authors:  Dan Wang; Li Zhong; M Abu Nahid; Guangping Gao
Journal:  Expert Opin Drug Deliv       Date:  2014-01-03       Impact factor: 6.648

3.  Influenza: viral vector delivers protective antibodies.

Authors:  Alexandra Flemming
Journal:  Nat Rev Drug Discov       Date:  2013-07-19       Impact factor: 84.694

4.  Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.

Authors:  Kevin O Saunders; Lingshu Wang; M Gordon Joyce; Zhi-Yong Yang; Alejandro B Balazs; Cheng Cheng; Sung-Youl Ko; Wing-Pui Kong; Rebecca S Rudicell; Ivelin S Georgiev; Lijie Duan; Kathryn E Foulds; Mitzi Donaldson; Ling Xu; Stephen D Schmidt; John-Paul Todd; David Baltimore; Mario Roederer; Ashley T Haase; Peter D Kwong; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2015-08       Impact factor: 5.103

Review 5.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

6.  A llama-derived antibody for flu.

Authors:  Saheli Sadanand
Journal:  Nat Biotechnol       Date:  2019-01-03       Impact factor: 54.908

7.  Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.

Authors:  G M Piperno; A López-Requena; A Predonzani; D Dorvignit; M Labrada; L Zentilin; O R Burrone; M Cesco-Gaspere
Journal:  Gene Ther       Date:  2015-07-16       Impact factor: 5.250

Review 8.  Adeno-associated virus: fit to serve.

Authors:  Eric Zinn; Luk H Vandenberghe
Journal:  Curr Opin Virol       Date:  2014-08-13       Impact factor: 7.090

9.  Intramuscular Adeno-Associated Virus-Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice.

Authors:  Laura P van Lieshout; Geoff Soule; Debra Sorensen; Kathy L Frost; Shihua He; Kevin Tierney; David Safronetz; Stephanie A Booth; Gary P Kobinger; Xiangguo Qiu; Sarah K Wootton
Journal:  J Infect Dis       Date:  2018-03-05       Impact factor: 5.226

Review 10.  State-of-the-art human gene therapy: part I. Gene delivery technologies.

Authors:  Dan Wang; Guangping Gao
Journal:  Discov Med       Date:  2014 Jul-Aug       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.